AI assistant
Dechra Pharmaceuticals PLC Board/Management Information 2023
4797_mang_2023-06-16_4c45bfdb-1271-4688-8b4f-c8c7d5d38a7c.html
Board/Management Information
Open in viewerOpens in your device viewer
/*<![CDATA[*/ /**/ /**/ /**/ sup{font-size:80%}link{ color: #0563C1 }visited{ color: #954F72 } .m{size:595.3pt 841.9pt;margin:49.65pt 72.0pt 0cm 72.0pt;}div.m{}p.ab{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";text-align:center}span.z{font-size:9.0pt;font-family:"Verdana","sans-serif"}p.a,li.a,div.a{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";}span.x{font-size:10.0pt;font-family:"Calibri","sans-serif"}span.w{font-size:11.0pt;font-family:"Calibri","sans-serif"}p.ac{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:12.0pt;font-family:"Verdana","sans-serif";color:black;text-align:center}p.ad{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:12.0pt;font-family:"Verdana","sans-serif";color:black;text-align:justify}span.v{font-size:10.0pt; font-family:"Calibri","sans-serif"} p.ae{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:12.0pt;font-family:"Verdana","sans-serif";color:black;text-align:justify;line-height:115%}span.t{font-size:11.0pt;line-height:115%;font-family:"Calibri","sans-serif"}span.r{font-size:10.0pt;line-height:115%;font-family:"Calibri","sans-serif"}p.h,li.h,div.h{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:12.0pt;font-family:"Verdana","sans-serif";color:black;}table.af{width:487.35pt;margin-left:-5.4pt;border-collapse:collapse}td.q{width:476.55pt;padding:0cm 5.4pt 0cm 5.4pt}p.ag{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";text-align:justify;line-height:115%}td.p{width:278.65pt;padding:0cm 5.4pt 0cm 5.4pt}td.o{width:187.1pt;padding:0cm 5.4pt 0cm 5.4pt}p.ah{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";text-align:justify} .fr-view-element{font-family: sans-serif;font-size: 12pt;line-height: 140%;padding: 20px;box-sizing: border-box;overflow-x: auto;min-height: 60px;text-align: left;margin-bottom: 10px;width: 837px;} .fr-view-element img{padding: 0 1px;} .fr-view-element .m{margin: 63.8pt 1.6cm 62.35pt 1.6cm;} .fr-view-element p{font-size: 10pt;} /**/ /**/ /**/ /*]]>*/ National Storage Mechanism | Additional information 
RNS Number : 0312D
Dechra Pharmaceuticals PLC
16 June 2023
16 June 2023
Dechra® Pharmaceuticals PLC
("Dechra" or "the Company")
Directorate Change
Further to the announcement made on 20 December 2022 which stated that Ishbel Macpherson intended to step down as a Non-Executive Director of the Company on 30 June 2023, she has informed the Board that she has decided to tender her resignation and step down from the Board on 22 June 2023.
Alison Platt, Chair, Dechra said:
Ishbel's contribution to the Board over the last ten years has been outstanding and we wish her well in her future endeavours. We would like to thank her for the additional time spent on the Board to enable Dechra to appoint a replacement Non-Executive Director and Remuneration Committee Chair.
| Enquiries: | |
| Dechra Pharmaceuticals PLC | |
| Ian Page, Chief Executive Officer | Office: +44 (0) 1606 814 730 |
| e-mail: [email protected] | |
| TooleyStreet Communications Ltd | |
| Fiona Tooley, Director e-mail: [email protected] |
Mobile: +44 (0) 7785 703 523 Office: +44 (0) 121 309 0099 |
About Dechra
Dechra is a global specialist veterinary pharmaceuticals and related products business. Our expertise is in the development, manufacture marketing and sales of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products.
Stock Code: Full Listing (Pharmaceuticals): DPH
LEI: 213800J4UVB5OWG8VX82
Trademarks
Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.
Market Abuse Regulation (MAR)
The information contained within this announcement may contain inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
BOAGPURCQUPWGUQ